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Background: Myxoid liposarcoma is the most common soft-tissue sarcoma that metastasizes to the peritoneal
cavity. Recently, an advanced intensity-modulated radiotherapy, known as helical tomotherapy, has been introduced
to improve target coverage, while reducing normal tissue radiation. Here, we report a case of myxoid liposarcoma
with multiple peritoneal seeding that was chemotherapy-refractory, but was successfully salvaged by helical
tomotherapy-based intraperitoneal radiotherapy.
Case presentation: A 71-year-old East-Asian male was initially diagnosed with myxoid liposarcoma in his left thigh by
excision. Six years later, the patient underwent a left pneumonectomy for metastatic myxoid liposarcoma in the left lung.
Since then, the patient was treated with two segmental resections, and multiple lines of chemotherapy, for repeated
recurrences in the peritoneal cavity. The patient underwent intraperitoneal radiotherapy followed by tumor boost
radiotherapy, as salvage treatment for chemotherapy-resistant metastatic peritoneal myxoid liposarcoma. The prescribed
dose was 24 Gy delivered in 15 fractions of 1.6 Gy over 3 weeks, followed by a 16 Gy boost dose administered in
eight fractions of 2 Gy, to multifocal peritoneal lesions. A positron emission tomography scan obtained 8 weeks
after completion of radiotherapy, showed a complete metabolic response of metastatic peritoneal lesions.
Radiotherapy was well tolerated, without any side effects. In a computed tomography scan obtained 20 weeks
after completion of radiotherapy, most of the peritoneal metastatic lesions had disappeared, except for two small
residual nodules.
Conclusion: This case suggests that low fraction-sized intraperitoneal radiotherapy (1.6 Gy administered once daily),
followed by a focal boost using helical tomotherapy, is a feasible treatment without side effects. It produced an
excellent tumor response, and durable intraperitoneal control for metastatic peritoneal myxoid liposarcoma.
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Figure 1 The patient was initially diagnosed with a myxoid liposarcoma in his left thigh by excision in 2000. A photomicrograph of the tumor
shows small proliferating spindle cells and lipoblasts in the myxoid stroma, findings consistent with myxoid liposarcoma. (a) Hematoxylin and
eosin stain (40X magnification). (b) Hematoxylin and eosin stain (200X magnification).
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Liposarcomas are malignant tumors of mesenchymal ori-
gin that arise from adipose tissue, and are the second most
frequent type (comprising 15–20%) of all soft tissue sarco-
mas (STS), with incidence peaks in the fourth to sixth de-
cades of life [1-3]. The World Health Organization
recognizes four subtypes: well-differentiated, dedifferen-
tiated, myxoid/round cell, and pleomorphic. Myxoid lipo-
sarcomas (MLS) tend to be low grade, and to metastasize
less frequently than the other types of liposarcoma. Unlike
other types of liposarcoma, however, MLS has a highFigure 2 Transverse (a-1, b-1, and c-1) and coronal (a-2, b-2, and c-2) com
images (40X: d, i, and n, 200X: e, j, and o) of metastatic myxoid liposarcoma
a left pneumonectomy for myxoid liposarcoma metastasizing to the left lu
segmental resection for a peritoneal metastatic myxoid liposarcoma, involv
then, the patient was treated by one additional segmental resection for a rpotential for extrapulmonary metastasis [4-6]. Peritoneal
metastases are considered an uncommon event in the nat-
ural history of STS. They may denote refractory disease,
and can cause bowel obstruction, bleeding, and perfor-
ation. Limited information is available regarding the
treatment of peritoneal metastasis from non-peritoneal
primary STS. MLS is the most common sarcoma that
metastasizes to the peritoneal area [7]. For patients
with progressive metastatic peritoneal disease, after
undergoing treatment with multiple lines of chemother-
apy and several surgical interventions, the therapeuticputed tomography, macroscopic (a-3, b-3, and c-3), and microscopic
. (a-1–a-5) Images from December 2006, when the patient underwent
ng. (b-1–b-5) Images from August 2009, when the patient underwent
ing the mesentery and subserosa of the jejunum. (c-1–c-5) Ever since
ecurred peritoneal metastatic myxoid liposarcoma in February 2012.
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supportive care only.
The excellent tumor control from whole abdominal
radiotherapy (WART) has been reported in ovarian
cancer patients with peritoneal seeding or carcinoma-
tosis [8-11]. However, conventional WART is a non-op-
timal technique because it does not sufficiently cover
the peritoneal cavity while sparing at-risk organs, such
as the kidneys, liver, and bone marrow. Recently,
advanced intensity-modulated radiotherapy (IMRT)
techniques, such as helical tomotherapy (HT) and volu-
metric modulated arc therapy (VMAT), have been in-
troduced to improve target coverage, while reducing
normal tissue damage. If WART using IMRT tech-
niques could spare the organs at risk, such as the
kidneys, liver, and bone marrow, it would be a mis-
nomer. Therefore, we have defined WART using IMRT
techniques as intraperitoneal radiotherapy (IPRT), be-
cause HT and VMAT focus more on intraperitoneally
seeded tumors, while avoiding major dose-limiting
organs in the abdomen. Here, we report a case in which
low fraction-sized IPRT using HT produced an
excellent tumor response and control for MLS with
multiple peritoneal seeding, without treatment-related
side effects.Figure 3 The three-dimensional radiotherapy for the rectal-shelf mass (a) D
metastatic myxoid liposarcoma, with a maximum size of 9.1 cm in the rect
of 40 Gy delivered in 20 fractions of 2 Gy over 4 weeks between Septembe
November 2012 after completion of radiotherapy, showed that the metasta
scan, obtained in May 2013, showed that the mass had decreased by 4.0 cCase presentation
In September 2013, a 71-year-old East-Asian male
visited our institution with a 5-month history of ab-
dominal pain, nausea, and constipation. Physical exam-
ination revealed a distended abdomen due to multiple,
non-tender masses, with no signs of peritonitis or
abdominal wall hernias. The Eastern Cooperative On-
cology Group (ECOG) performance status of the
patient was “1”. His medical history included a huge,
non-tender, deep, rubbery MLS (pT2bN0M0, positive
resection margin), with a maximum size of 20 cm at
the medial side of the left thigh. The tumor had been
treated by excision (Figure 1) and postoperative RT at a
dose of 63 grays (Gy) delivered in 35 fractions of 1.8 Gy
over 7 weeks in 2000. Six year later in 2006, the patient
underwent a left pneumonectomy for a MLS metasta-
sizing to the left lung (Figure 2 a-1–a-5). The removal
was radical, with free margins and an intact tumor
capsule. Postoperatively, no adjuvant therapy was indi-
cated, and close follow-up was recommended. In Au-
gust 2009, the patient underwent segmental resection
for two peritoneal metastatic nodules (size: 15 × 15 ×
11 cm and 14 × 9 × 9 cm, respectively) involving the
mesentery and subserosa of the jejunum (Figure 2 b-1–b-5),
and adjuvantly received 6 cycles of chemotherapy withose distribution for the three-dimensional radiotherapy plan for the
ovesical pouch. The patient underwent salvage radiotherapy at a dose
r and October 2012. (b) A computed tomography scan, obtained in
tic mass had decreased by 6.9 cm in size. (c) A computed tomography
m in size.
Figure 4 Coronal images of computed tomography or positron emission tomography scans showing a regression of peritoneal metastases. (a)
Contrast-enhanced abdominal computed tomography scan showing multifocal metastatic peritoneal nodules (white arrows) in September 2013.
The patient completed intraperitoneal radiotherapy followed immediately by tumor boost radiotherapy. (b) Surveillance by positron emission
tomography scan, obtained 8 weeks after completion of radiotherapy, showed a complete metabolic response of metastatic peritoneal lesions.
(c) A contrast-enhanced computed tomography scan, obtained in March 2014 after completion of radiotherapy, shows that most of the
metastatic peritoneal lesions had disappeared.
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segmental resection was performed for a recurrent
peritoneal metastatic MLS (size: 13 × 13 × 7 cm) in
February 2012 (Figure 2 c-1–c-5). Abdominal com-
puted tomography (CT) imaging in May 2012 showed a
progressive mass in the rectovesical pouch. It caused
symptoms of abdominal pain and constipation. The
patient received two cycles of chemotherapy with gem-
citabine and docetaxel, followed by two cycles of dacar-
bazine. Despite this chemotherapy, the rectovesical
pouch mass progressed. The patient refused any further
chemotherapy. He was referred for salvage RT of his
progressive, rectal-shelf mass. The radiation prescribed
for the rectal-shelf mass was 40 Gy, to be delivered in
20 fractions of 2 Gy over 4 weeks, between September
2012 and October 2012 (Figure 3). No acute skin or
gastrointestinal toxicity was reported. This treatment
provided an excellent tumor response, and symptom
relief for the patient. The tumor mass slowly regressed
over the course of a year.
However, follow-up abdominal CT in September 2013,
showed multifocal peritoneal nodules with fatty compo-
nents within the mesentery of the jejunum, ileum, and
ascending colon (Figures 4 a and 5 a). The patient re-
fused further salvage chemotherapy, but gave informed
consent for treatment with IPRT using HT. A dose of 24
Gy was prescribed, to be delivered in 15 fractions of
1.6 Gy over 3 weeks, followed by a 16 Gy boost dose in
8 fractions of 2 Gy delivered on each residual metastaticFigure 5 Transverse images of a contrast-enhanced abdominal computed tom
abdominal computed tomography scan from September 2013, showed multif
intraperitoneal radiotherapy. (b) Surveillance by computed tomography scan, o
complete response of five nodules (1, 2, 5, 6, 7, and 8) and a partial response o
in March 2014 after completion of radiotherapy, showed that most of the met
had decreased in size by about 0.8–1 cm (3 and 4). The asterisk (*) indicates a speritoneal lesion. The clinical target volume (CTV) was
defined as the whole peritoneal cavity, supplemented by
the aortocaval and iliac nodes, as described by Duthoy et
al. [10]. The following at-risk organs were delineated:
the liver, both kidneys, and the spine. An IPRT dose dis-
tribution in the transverse and coronal plane is illus-
trated in Figure 6. Average doses to the liver, and right
and left kidneys were 16.9 Gy, 13.8 Gy, and 14.1 Gy,
respectively, which are sufficiently lower than the limit-
ing doses. The second CT scan was used to generate an
adaptive HT-based IMRT plan, which recommended a
16 Gy boost in 8 fractions of 2 Gy for residual multifocal
peritoneal lesions that had shrunken after IPRT. The
residual tumor was defined as the gross tumor volume
(GTVboost). For second treatment planning, the GTVboost
was equal to the CTVboost. The planning target volume
(PTVboost) was made by three-dimensional expansion of
the CTVboost with 0.5 cm axial, and 1 cm superior/inferior
margins. A RT boost dose distribution in the coronal
plane is illustrated in Figure 7. The patient completed
IPRT, followed by tumor boost RT, between September
2013 and October 2013.
Clinical symptoms and treatment-related side effects
were monitored weekly during treatment, at the end of
treatment, and monthly thereafter. RT was well toler-
ated, without any side effects, such as bone marrow sup-
pression, nausea, diarrhea, or abdominal cramps. The
patient did not experience tumor lysis syndrome. Sur-
veillance by positron emission tomography (PET) scanography scan showing a regression of the peritoneal metastases. (a) An
ocal metastatic peritoneal nodules (numbered from ‘1’ to ‘8’) before
btained in December 2013 after completion of radiotherapy, showed a
f three nodules (1, 3, and 4). (c) A computed tomography scan, obtained
astatic peritoneal lesions had disappeared, except two small nodules that
imple benign cyst.
Figure 6 Radiation dose distribution for intraperitoneal radiotherapy using helical tomotherapy-based intensity-modulated radiotherapy, with
particular attention to representative dosimetry within the liver (a-c) bilateral kidneys (d-f), and bone marrow (g-i). Transverse (a, d, and g),
coronal (b, e, and h), and sagittal computed tomography images (c, f, and i) with isodose radiation color contour maps are provided.
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sponse of the peritoneal metastatic lesions (Figure 4 b).
Furthermore, the CT scan obtained the same day
showed a complete response for 5 nodules and a partial
response for the 3 others (Figure 5 b). The ECOG per-
formance status of the patient remained “0”. The patient,
who had initially presented with abdominal pain, nausea,
and constipation, obtained the return of peristalsis, nor-
mal food intake, and normalization of stools. In a CT
scan obtained in March 2014, 5 months post completion
of RT, most of the peritoneal metastatic lesions had dis-
appeared, except for two small nodules that had de-
creased to 1.0 cm and 0.8 cm from 7.2 cm and 2.4 cm in
size, respectively (Figures 4 c and 5 c). The patient has
not developed late hematologic, genitourinary, or gastro-
intestinal toxicity within the 9 months post RT.
Discussion
Using the case presented here, we report on the effective
salvage of recurrent chemotherapy-resistant peritoneal le-
sions after segmental resection for a metastatic peritonealMLS, by IPRT using HT. Although some studies have sug-
gested that MLS tends to be relatively more radiosensitive
than other types of STS, with high rates of regression and
even complete clinical response [12,13], RT, covering the
whole intraperitoneum, has not been well established as a
salvage treatment in metastatic peritoneal MLS. However,
it has been reported that conventional WART doses be-
tween 20 and 30 Gy produce high tumor response rates of
50–70% in the treatment of epithelial ovarian carcinoma
[14,15]. With this in mind, we exploited IPRT using HT
for this challenging case of metastatic chemotherapy-
resistant peritoneal MLS.
Limited data are available on the treatment for metastatic
peritoneal relapse from MLS. Surgery may be the treat-
ment of choice for those patients with complications, such
as incomplete intestinal obstruction, abdominal pain, ab-
dominal distension, gastrointestinal bleeding, urinary ob-
struction, and anorexia [16,17]. However, given the reports
of repetitive peritoneal relapse following surgical excision,
treatment with re-excisions may not be appropriate. For
high-grade or recurrent or metastatic lesions, conventional
Figure 7 A boost radiotherapy dose distribution in the coronal plane. The gross tumor volume was equal to the clinical target volume. The planning
target volume was made by a three dimensional expansion of the clinical target volume, with 0.5 cm axial and 1 cm superior/inferior margins.
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dicated [18,19,17,16]. In a recent randomized controlled
phase III trial [18], the median progression-free survival
was significantly higher for the combination arm using
doxorubicin and ifosfamide than for the doxorubicin alone
arm (7.4 vs 4.6 months; p = 0.003). The combination arm
also had a higher overall response rate than the doxorubi-
cin alone arm (26% vs. 14%; p < 0.0006). Recently, a
marine-derived compound, trabectedin, has been intro-
duced, and is believed to be effective [17,16,20]. In a pro-
spective phase II study of neoadjuvant trabectedin in
patients with advanced localized myxoid liposarcoma [20],
the objective response rate was 24% and no disease pro-
gression was reported. The use of intraoperative radiother-
apy (IORT) has provided encouraging results in patients
with primary and recurrent retroperitoneal STS [21-23]. A
protocol involving maximal tumor resection and IORT,
with or without external beam RT, might be effective for
local control in patients with metastatic peritoneal relapse
from MLS.
Conventional WART has been effective in intraperito-
neal tumor control to some degree. However, it would not
have sufficiently covered the whole intraperitoneal cavity,
as we wished to spare the liver and kidneys using the basic
technique of anterior to posterior (AP) and posterior to
anterior (PA) direction beam delivery. Modern advances
in RT techniques, such as IMRT, have allowed us to over-
come the shortcomings of conventional WART [10,24]. Aretrospective study showed that IPRT, delivered using
IMRT, could offer significant palliation in the case of peri-
toneal metastatic ovarian cancer [11]. IPRT using HT
provides superior target coverage, while simultaneously
dose-limiting critical at-risk organs, when compared to
conventional WART. HT can improve radiation dose
coverage of peritoneal surfaces, especially near the kidney
and liver, due to the freedom of beam direction and
delicate intensity modulation. HT can also deliver lower
radiation doses to the liver, bilateral kidneys, and bone
marrow [25]. The broad practical use of IPRT is limited by
an extended radiation beam field lengths of >40 cm, mul-
tiple dose isocenters in the abdomen and pelvis, and treat-
ment complexity. Compared to other IMRT techniques,
IPRT using HT can obviate extended beam field lengths
and multiple dose isocenters owing its continuous helical
delivery of radiation. Taking all these facts into consider-
ation, we believed that IPRT using HTcould offer effective
symptom relief and tumor control in the case of peritoneal
metastatic MLS, without significant hematologic, genito-
urinary, or gastrointestinal toxicity.
No consensus currently exists regarding the optimum
IPRT dose and fractionation schedule for metastatic
peritoneal lesions from MLS. Future research should
focus on obtaining the lowest radiation dose that in-
duces symptomatic relief without significant toxicity.
Perhaps a more modest dose might obtain the same pal-
liation as reported in the present study. In our case, the
Choi et al. BMC Research Notes  (2015) 8:179 Page 8 of 9low fraction-sized IPRT schedule (1.6 Gy given once
daily) appears to be associated with the lack of any side
effects experienced by the patient, such as bone marrow
suppression, nausea, diarrhea, or abdominal cramps. Al-
though there is an understanding of the mechanism of
cell death by radiation at conventional fraction size (1.8–
3.0 Gy per fraction), the effect and safety of IPRTat a lower
fraction size (<1.8 Gy) on patients with a peritoneal meta-
static MLS is still unknown, and should be further investi-
gated with clinical observation and preclinical studies.
Generally, patients with MLS have a good prognosis,
and they have the potential for gaining maximum benefit
from techniques that minimize the side effects of RT
[13]. MLS primarily metastasizes to extrapulmonary
sites, most commonly the peritoneal cavity, in contrast
with other STS [4-6]. The low pulmonary metastatic po-
tential of MLS provides the patients with a relatively
long survival time [26]. MLS has been reported to be
more radiosensitive compared to other STS [12,13].
Therefore, IPRT using HT could be a effective treatment
for patients with peritoneal metastatic MLS, although it
is most likely to be a palliative procedure. When the
therapeutic options are very limited, IPRT using an ad-
vanced technique like IMRT, could be a good option for
patients with progressive metastatic peritoneal disease
after undergoing treatment with multiple lines of pallia-
tive chemotherapy, and several surgical interventions.
Conclusion
The present case report shows that low fraction-sized
IPRT (1.6 Gy given once daily), followed by tumor boost
RT using HT, provided excellent tumor control and
symptom relief for a patient with bulky multifocal ab-
dominal tumors, identified as a metastatic peritoneal
MLS. Our findings, taken together with reports from the
literature, emphasize that radiosensitivity in other types
of cancer could translate into excellent tumor control
when IPRT using HT is appropriately applied.
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